CN113633607A - 含有盐酸氨溴索的药物组合物及其制备方法 - Google Patents
含有盐酸氨溴索的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN113633607A CN113633607A CN202110944875.7A CN202110944875A CN113633607A CN 113633607 A CN113633607 A CN 113633607A CN 202110944875 A CN202110944875 A CN 202110944875A CN 113633607 A CN113633607 A CN 113633607A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- ambroxol hydrochloride
- agent
- sweetener
- purified water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 63
- 229960000985 ambroxol hydrochloride Drugs 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 24
- 239000003765 sweetening agent Substances 0.000 claims abstract description 24
- 238000001914 filtration Methods 0.000 claims abstract description 21
- 239000003755 preservative agent Substances 0.000 claims abstract description 21
- 239000002562 thickening agent Substances 0.000 claims abstract description 19
- 125000003118 aryl group Chemical group 0.000 claims abstract description 16
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- 230000008569 process Effects 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000008213 purified water Substances 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 238000007789 sealing Methods 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 11
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 239000004677 Nylon Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 229920001778 nylon Polymers 0.000 claims description 6
- 239000003002 pH adjusting agent Substances 0.000 claims description 6
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 5
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 239000000337 buffer salt Substances 0.000 claims description 4
- 229940100688 oral solution Drugs 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000002535 acidifier Substances 0.000 claims description 3
- 238000009924 canning Methods 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 229940100692 oral suspension Drugs 0.000 claims description 3
- 239000007961 artificial flavoring substance Substances 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 21
- 210000000214 mouth Anatomy 0.000 abstract description 16
- 235000019640 taste Nutrition 0.000 abstract description 15
- 238000011049 filling Methods 0.000 abstract description 14
- 230000014759 maintenance of location Effects 0.000 abstract description 9
- 230000002335 preservative effect Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 7
- 206010007269 Carcinogenicity Diseases 0.000 abstract description 6
- 230000007670 carcinogenicity Effects 0.000 abstract description 6
- 231100000260 carcinogenicity Toxicity 0.000 abstract description 6
- 244000005700 microbiome Species 0.000 abstract description 6
- 239000004014 plasticizer Substances 0.000 abstract description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 5
- 208000003455 anaphylaxis Diseases 0.000 abstract description 5
- 238000009776 industrial production Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 32
- 235000019658 bitter taste Nutrition 0.000 description 18
- 239000000203 mixture Substances 0.000 description 14
- 241000220223 Fragaria Species 0.000 description 13
- 235000016623 Fragaria vesca Nutrition 0.000 description 13
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 13
- 239000004376 Sucralose Substances 0.000 description 13
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 13
- 235000019408 sucralose Nutrition 0.000 description 13
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 11
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 230000002045 lasting effect Effects 0.000 description 9
- 239000004698 Polyethylene Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000005711 Benzoic acid Substances 0.000 description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 5
- 239000004695 Polyether sulfone Substances 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 5
- 229920006393 polyether sulfone Polymers 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 4
- 235000012907 honey Nutrition 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000022 bacteriostatic agent Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical class C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- RMLYXMMBIZLGAQ-UHFFFAOYSA-N (-)-monatin Natural products C1=CC=C2C(CC(O)(CC(N)C(O)=O)C(O)=O)=CNC2=C1 RMLYXMMBIZLGAQ-UHFFFAOYSA-N 0.000 description 1
- RMLYXMMBIZLGAQ-HZMBPMFUSA-N (2s,4s)-4-amino-2-hydroxy-2-(1h-indol-3-ylmethyl)pentanedioic acid Chemical compound C1=CC=C2C(C[C@](O)(C[C@H](N)C(O)=O)C(O)=O)=CNC2=C1 RMLYXMMBIZLGAQ-HZMBPMFUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 244000173610 Mentha aquatica Species 0.000 description 1
- 235000012629 Mentha aquatica Nutrition 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960005174 ambroxol Drugs 0.000 description 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000012658 bimolecular nucleophilic substitution Methods 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组分 | 实施例1 | 实施例2 | 实施例3 | 实施例4 |
盐酸氨溴索 | 300mg | 600mg | 300mg | 600mg |
三氯蔗糖 | 300mg | 60mg | 200mg | 200mg |
DL-苹果酸 | 60mg | 6mg | 30mg | 30mg |
香地草莓香精 | 600mg | 60mg | 500mg | 500mg |
纯化水 | 补全至100ml | 补全至100ml | 补全至100ml | 补全至100ml |
组分 | 用量 |
盐酸氨溴索 | 600mg |
羟乙纤维素 | 600mg |
三氯蔗糖 | 200mg |
DL-苹果酸 | 30mg |
香地草莓香精 | 500mg |
纯化水 | 补全至100ml |
组分 | 用量 |
盐酸氨溴索 | 600mg |
苯甲酸 | 80mg |
三氯蔗糖 | 200mg |
DL-苹果酸 | 30mg |
香地草莓香精 | 500mg |
纯化水 | 补全至100ml |
分组 | 口感 |
实施例1 | 口味适宜,入口苦,苦味持续约4秒 |
实施例2 | 口味适宜,入口苦,苦味持续约3秒 |
实施例3 | 口味适宜,入口苦,苦味持续约3秒 |
实施例4 | 口味适宜,入口苦,苦味持续3秒 |
对比例1 | 口味适宜,入口苦,苦味持续10秒 |
对比例2 | 口味适宜,入口苦,苦味持续10秒 |
对比例3 | 口味适宜,入口苦,苦味持续4秒 |
市售 | 口味适宜,入口苦,苦味持续10秒 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110944875.7A CN113633607A (zh) | 2021-08-17 | 2021-08-17 | 含有盐酸氨溴索的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110944875.7A CN113633607A (zh) | 2021-08-17 | 2021-08-17 | 含有盐酸氨溴索的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113633607A true CN113633607A (zh) | 2021-11-12 |
Family
ID=78422458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110944875.7A Pending CN113633607A (zh) | 2021-08-17 | 2021-08-17 | 含有盐酸氨溴索的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113633607A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2169557C1 (ru) * | 1999-12-22 | 2001-06-27 | Александр Афанасьевич Яремчук | Сироп амброксола для лечения бронхопульмональных заболеваний |
CN101152181A (zh) * | 2006-09-29 | 2008-04-02 | 北京德众万全药物技术开发有限公司 | 含有氯雷他定和盐酸氨溴索的液体组合物 |
CN101204386A (zh) * | 2006-12-19 | 2008-06-25 | 北京德众万全药物技术开发有限公司 | 含有硫酸沙丁胺醇和盐酸氨溴索的液体组合物 |
CN101961307A (zh) * | 2010-09-14 | 2011-02-02 | 武汉人福药业有限责任公司 | 治疗呼吸道疾病的口服液及其制备方法 |
CN105193707A (zh) * | 2014-06-30 | 2015-12-30 | 南京瑞尔医药有限公司 | 一种盐酸氨溴索口服溶液及其制备方法 |
WO2018182546A1 (en) * | 2017-03-27 | 2018-10-04 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Stabilized pharmaceutical syrup composition comprising terbutaline sulphate and ambroxol hydrochloride |
CN111494314A (zh) * | 2020-06-01 | 2020-08-07 | 上海信谊金朱药业有限公司 | 一种盐酸氨溴索口服溶液及其制备方法 |
-
2021
- 2021-08-17 CN CN202110944875.7A patent/CN113633607A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2169557C1 (ru) * | 1999-12-22 | 2001-06-27 | Александр Афанасьевич Яремчук | Сироп амброксола для лечения бронхопульмональных заболеваний |
CN101152181A (zh) * | 2006-09-29 | 2008-04-02 | 北京德众万全药物技术开发有限公司 | 含有氯雷他定和盐酸氨溴索的液体组合物 |
CN101204386A (zh) * | 2006-12-19 | 2008-06-25 | 北京德众万全药物技术开发有限公司 | 含有硫酸沙丁胺醇和盐酸氨溴索的液体组合物 |
CN101961307A (zh) * | 2010-09-14 | 2011-02-02 | 武汉人福药业有限责任公司 | 治疗呼吸道疾病的口服液及其制备方法 |
CN105193707A (zh) * | 2014-06-30 | 2015-12-30 | 南京瑞尔医药有限公司 | 一种盐酸氨溴索口服溶液及其制备方法 |
WO2018182546A1 (en) * | 2017-03-27 | 2018-10-04 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Stabilized pharmaceutical syrup composition comprising terbutaline sulphate and ambroxol hydrochloride |
CN111494314A (zh) * | 2020-06-01 | 2020-08-07 | 上海信谊金朱药业有限公司 | 一种盐酸氨溴索口服溶液及其制备方法 |
Non-Patent Citations (2)
Title |
---|
国家药典委员会: "《中国人民共和国药典 2010版》", 31 January 2010, 中国医药科技出版社, pages: 766 * |
温辉梁: "《生物化工产品生产技术》", 31 December 2004, 江西科学技术出版社, pages: 153 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA025640B1 (ru) | Водная композиция, содержащая бромгексин | |
JP5695029B2 (ja) | β遮断薬を含む小児用溶液 | |
EP2838510B1 (en) | Atomoxetine solution | |
EP3003384B1 (en) | Oral solution comprising atomoxetine hydrochloride | |
KR100841893B1 (ko) | 프레가발린 조성물 | |
JP2015522624A5 (zh) | ||
CN111437247A (zh) | 一种托莫西汀口服液的制备方法 | |
CN114159385A (zh) | 含有硫酸沙丁胺醇的药物组合物及其制备方法 | |
KR20160036000A (ko) | 수용성 아줄렌 및 알킬피리디늄 할라이드를 포함하는 구강 스프레이 조성물 | |
JP4959335B2 (ja) | メチルフェニデート溶液および関連する投与および製造方法 | |
CN113633607A (zh) | 含有盐酸氨溴索的药物组合物及其制备方法 | |
JP5660817B2 (ja) | スマトリプタンコハク酸塩を含有する内用液剤 | |
CN113975262A (zh) | 含有福多司坦的药物组合物及其制备方法 | |
CN111374942A (zh) | 一种甾体类肌松药注射液及其制备方法 | |
CN115475141A (zh) | 一种地氯雷他定口服溶液及其制备方法 | |
CN110327293B (zh) | 一种右美沙芬愈创甘油醚口服液体制剂 | |
JP4403587B2 (ja) | 低pHで安定な生薬エキス配合液剤 | |
CN114699368A (zh) | 一种拉考沙胺口服溶液及其制备方法 | |
CN112076154A (zh) | 盐酸托莫西汀口服液及其制备方法 | |
CN115040516A (zh) | 一种含盐酸丙卡特罗的药物组合物及其制备方法和应用 | |
CN113995721A (zh) | 一种盐酸氨溴索口腔喷雾溶液及其制备方法 | |
EP3777829B1 (en) | Oral pharmaceutical solutions comprising nortriptyline hydrochloride | |
WO2014060324A1 (en) | Aripiprazole formulations | |
KR102530365B1 (ko) | 아세트아미노펜 젤리 제제 | |
CN116531383A (zh) | 含吡嘧司特钾的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 102629 No. 5, Xiangrui street, biomedical base, Daxing District, Beijing Applicant after: Beijing Sihuan Kebao Pharmaceutical Co.,Ltd. Address before: 102629 No. 5, Xiangrui street, biomedical base, Daxing District, Beijing Applicant before: BEIJING SIHUAN KEBAO PHARMACEUTICAL Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240103 Address after: 236600 No.1 Xianghe Road, Taihe County Economic Development Zone, Fuyang City, Anhui Province Applicant after: Anhui Sihuan Kebao Pharmaceutical Co.,Ltd. Address before: 102629 No. 5, Xiangrui street, biomedical base, Daxing District, Beijing Applicant before: Beijing Sihuan Kebao Pharmaceutical Co.,Ltd. |